Search for a trial

An interventional, prospective IVD device study for the testing of DNA extracted from tumor tissue biopsy samples from adult participants with metastatic Non-Small Cell Lung Cancer (NSCLC) for potential inclusion in the MSD Phase 3 clinical trial (Protocol No MK-1084-004) to demonstrate clinical performance of the therascreen® KRAS RGQ PCR Kit.

To utilize the therascreen KRAS RGQ PCR Kit (KRAS Kit) as a screening test to identify KRAS G12C mutations in newly diagnosed metastatic NSCLC participants and thereby determine eligibility for enrolment into the Phase 3 clinical study (MK-1084-004…

Study to Assess How Well a Laboratory Test Measures Levels of a Specific Marker in Lung Cancer Samples from a Clinical Trial

The primary objective of this study is to evaluate the clinical performance of the VENTANA PD-L1 (SP263) CDx Assay in terms of its ability to identify patients with non-squamous stage IV or recurrent NSCLC who may benefit from treatment with…

Use of GRAIL NSCLC ctDNA Assay in AstraZeneca Study D926TC00001 (TROPION-Lung12)

To evaluate the performance of the GRAIL NSCLC ctDNA Assay when used to identify patients with stage I adenocarcinoma NSCLC who are ctDNA positive as part of the screening process for the clinical study TROPION-Lung12.